celecoxib has been researched along with Local Neoplasm Recurrence in 58 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the role of celecoxib as an addition to conventional therapy for women with ERBB2 (formerly HER2)-negative primary breast cancer." | 9.41 | Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial. ( Bartlett, J; Bliss, JM; Borley, A; Coleman, R; Coombes, RC; Denkert, C; Dibble, T; Evans, A; Grieve, R; Hicks, J; Kilburn, L; Kunze, CA; Loibl, S; Lu, XL; Makris, A; Mansi, J; Mehta, K; Mousa, K; Murray, E; Palmieri, C; Rautenberg, B; Rhein, U; Schmidt, M; Tovey, H; von Minckwitz, G, 2021) |
| "Genetic polymorphisms in multiple inflammation-related genes appear to interact with celecoxib on adenoma recurrence and its attendant toxicity, particularly cardiovascular toxicity/symptoms." | 9.17 | Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study. ( Arber, N; Coghill, AE; Duggan, D; Galazan, L; Gigic, B; Hummler, S; Kazanov, D; Kotzmann, J; Kraus, S; Makar, KW; Naumov, I; Poole, EM; Scherer, D; Toriola, AT; Ulrich, CM, 2013) |
| "Postmenopausal women with estrogen receptor (ER) and/or progesterone (PR) positive stages II-III breast cancers received 8 weeks of exemestane 25 mg daily, followed by 8 weeks of exemestane 25 mg daily and celecoxib 400 mg twice daily." | 9.15 | Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer. ( Brueggemeier, RW; Layman, RM; Lehman, AM; Lustberg, MB; Mrozek, E; Povoski, SP; Ramaswamy, B; Ruppert, AS; Shapiro, CL; Shiels, DR; Sugimoto, Y; Zhao, W; Ziegler, RM, 2011) |
| "The Adenoma Prevention with Celecoxib Trial examined the efficacy and safety of the cyclooxygenase (Cox)-2 inhibitor, celecoxib, for sporadic colorectal adenoma prevention in patients at high risk for colorectal cancer." | 9.14 | Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. ( Bagheri, D; Bertagnolli, MM; Breazna, A; Burn, J; Chung, DC; Collins, NT; Dewar, T; Eagle, CJ; Foley, TR; Hawk, ET; Hoffman, N; Kim, K; Macrae, F; Pruitt, RE; Redston, M; Rosenstein, RB; Saltzman, JR; Salzberg, B; Sylwestrowicz, T; Tang, J; Umar, A; Zauber, AG, 2009) |
| "In the current study, the authors report a Phase II trial of irinotecan (CPT-11), a topoisomerase I inhibitor active against malignant glioma (MG), with celecoxib, a selective COX-2 inhibitor, among MG patients with recurrent disease." | 9.11 | Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. ( Badruddoja, M; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Quinn, JA; Reardon, DA; Rich, JN; Vredenburgh, J, 2005) |
| "Discovery phase: 1,406 Caucasian patients (139 advanced adenoma cases and 1,267 controls) from the Adenoma Prevention with Celecoxib (APC) trial were included in a genome-wide association study (GWAS) to identify variants associated with postpolypectomy disease recurrence." | 8.89 | Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study. ( Baird, PN; Bertagnolli, MM; Carvajal-Carmona, LG; Chu, JH; Dunlop, M; Gibbs, P; Houlston, RS; Kubo, M; Lipton, L; Martin, NG; Matsuda, K; Montgomery, GW; Nakamura, Y; Ratain, MJ; Sieber, O; Tomlinson, I; Wang, J; Weiss, ST; Young, J; Zauber, AG, 2013) |
| "Recurrent respiratory papillomas, caused by human papillomaviruses, are premalignant tumors that overexpress the epidermal growth factor receptor (EGFR)." | 7.73 | Epidermal growth factor-induced cyclooxygenase-2 expression is mediated through phosphatidylinositol-3 kinase, not mitogen-activated protein/extracellular signal-regulated kinase kinase, in recurrent respiratory papillomas. ( Abramson, AL; Dannenberg, AJ; Shikowitz, MJ; Steinberg, BM; Wu, R, 2005) |
| "Celecoxib was well tolerated, with similar adverse events and quality-of-life in both arms." | 6.76 | A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. ( Czerniak, BA; De la Cerda, J; Eagle, C; Grossman, HB; Lee, JJ; Lerner, SP; Liu, S; Palmer, JL; Richmond, E; Sabichi, AL; Viner, JL, 2011) |
| "In patients with advanced colorectal cancer, we compared the efficacy of celecoxib at two different doses (200 mg twice day and 400 mg twice daily) with placebo." | 5.41 | Selective COX-2 inhibitors do not increase gastrointestinal reactions after colorectal cancer surgery: a systematic review and meta-analysis. ( Bai, H; Hu, T; Li, Y; Liu, CJ; Liu, F; Tang, W; Wang, D; Yin, L; Yin, X, 2023) |
| "To evaluate the role of celecoxib as an addition to conventional therapy for women with ERBB2 (formerly HER2)-negative primary breast cancer." | 5.41 | Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial. ( Bartlett, J; Bliss, JM; Borley, A; Coleman, R; Coombes, RC; Denkert, C; Dibble, T; Evans, A; Grieve, R; Hicks, J; Kilburn, L; Kunze, CA; Loibl, S; Lu, XL; Makris, A; Mansi, J; Mehta, K; Mousa, K; Murray, E; Palmieri, C; Rautenberg, B; Rhein, U; Schmidt, M; Tovey, H; von Minckwitz, G, 2021) |
| "Neutropenia was the main side effect of the metronomic therapy." | 5.38 | Treatment for recurrent medulloblastoma with intrathecal liposomal cytarabine and systemic metronomic combination therapy. ( Kivivuori, SM; Nygaard, R, 2012) |
| "Celecoxib, which was approved by Health Canada for familial adenomatous polyposis coli, was offered to 27 patients with surgically incurable recurrent melanoma, 87 percent of whom had stage M1c disease." | 5.33 | Clinical activity of celecoxib in metastatic malignant melanoma. ( Wilson, KS, 2006) |
| "Celecoxib was not shown to reduce the risk of recurrence in intermediate- or high-risk non-muscle-invasive bladder cancer (NMIBC), although celecoxib was associated with delayed time to recurrence in pT1 NMIBC patients." | 5.30 | BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). ( Andrews, S; Blazeby, J; Bogle, R; Brough, R; Burnett, S; Cresswell, J; Cruickshank, C; Hall, E; Huddart, R; Johnson, M; Kelly, JD; Madaan, S; Maynard, L; Mostafid, H; Palmer, A; Porta, N; Protheroe, A; Tan, WS, 2019) |
| " Twenty patients with recurrent and 3 with refractory high-risk neuroblastoma were treated by the metronomic concept using celecoxib, cyclophosphamide, vinblastine, and etoposide for up to 24 months." | 5.24 | Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma. ( Belogurova, M; Berthold, F; Ernst, A; Hömberg, M; Mazanek, P; Proleskovskaya, I; Sterba, J, 2017) |
| "With a lower efficacy than Sou-Medrol in decreasing postoperative inflammation, celecoxib produces a better effect in inhibiting COX-2 expression, but it does not lower postoperative recurrence rate of rectal cancer." | 5.20 | [Perioperative immunomodulatory therapy does not decrease postoperative recurrence rate of rectal cancer]. ( Gan, ZM; Li, L; Liu, D; Lv, DH; Wang, XD, 2015) |
| "Genetic polymorphisms in multiple inflammation-related genes appear to interact with celecoxib on adenoma recurrence and its attendant toxicity, particularly cardiovascular toxicity/symptoms." | 5.17 | Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study. ( Arber, N; Coghill, AE; Duggan, D; Galazan, L; Gigic, B; Hummler, S; Kazanov, D; Kotzmann, J; Kraus, S; Makar, KW; Naumov, I; Poole, EM; Scherer, D; Toriola, AT; Ulrich, CM, 2013) |
| "Postmenopausal women with estrogen receptor (ER) and/or progesterone (PR) positive stages II-III breast cancers received 8 weeks of exemestane 25 mg daily, followed by 8 weeks of exemestane 25 mg daily and celecoxib 400 mg twice daily." | 5.15 | Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer. ( Brueggemeier, RW; Layman, RM; Lehman, AM; Lustberg, MB; Mrozek, E; Povoski, SP; Ramaswamy, B; Ruppert, AS; Shapiro, CL; Shiels, DR; Sugimoto, Y; Zhao, W; Ziegler, RM, 2011) |
| "The Adenoma Prevention with Celecoxib Trial examined the efficacy and safety of the cyclooxygenase (Cox)-2 inhibitor, celecoxib, for sporadic colorectal adenoma prevention in patients at high risk for colorectal cancer." | 5.14 | Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. ( Bagheri, D; Bertagnolli, MM; Breazna, A; Burn, J; Chung, DC; Collins, NT; Dewar, T; Eagle, CJ; Foley, TR; Hawk, ET; Hoffman, N; Kim, K; Macrae, F; Pruitt, RE; Redston, M; Rosenstein, RB; Saltzman, JR; Salzberg, B; Sylwestrowicz, T; Tang, J; Umar, A; Zauber, AG, 2009) |
| "In the current study, the authors report a Phase II trial of irinotecan (CPT-11), a topoisomerase I inhibitor active against malignant glioma (MG), with celecoxib, a selective COX-2 inhibitor, among MG patients with recurrent disease." | 5.11 | Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. ( Badruddoja, M; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Quinn, JA; Reardon, DA; Rich, JN; Vredenburgh, J, 2005) |
| "Discovery phase: 1,406 Caucasian patients (139 advanced adenoma cases and 1,267 controls) from the Adenoma Prevention with Celecoxib (APC) trial were included in a genome-wide association study (GWAS) to identify variants associated with postpolypectomy disease recurrence." | 4.89 | Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study. ( Baird, PN; Bertagnolli, MM; Carvajal-Carmona, LG; Chu, JH; Dunlop, M; Gibbs, P; Houlston, RS; Kubo, M; Lipton, L; Martin, NG; Matsuda, K; Montgomery, GW; Nakamura, Y; Ratain, MJ; Sieber, O; Tomlinson, I; Wang, J; Weiss, ST; Young, J; Zauber, AG, 2013) |
| "Recurrent respiratory papillomas, caused by human papillomaviruses, are premalignant tumors that overexpress the epidermal growth factor receptor (EGFR)." | 3.73 | Epidermal growth factor-induced cyclooxygenase-2 expression is mediated through phosphatidylinositol-3 kinase, not mitogen-activated protein/extracellular signal-regulated kinase kinase, in recurrent respiratory papillomas. ( Abramson, AL; Dannenberg, AJ; Shikowitz, MJ; Steinberg, BM; Wu, R, 2005) |
| "Among patients with stage III colon cancer, the addition of celecoxib for 3 years, compared with placebo, to standard adjuvant chemotherapy did not significantly improve disease-free survival." | 3.01 | Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial. ( Bendell, JC; Bertagnolli, M; Blanke, C; Couture, F; Fuchs, CS; Goldberg, RM; Grothey, A; Guthrie, KA; Hochster, HS; Kuebler, P; Kumar, P; Kumthekar, P; Lewis, D; Meyer, J; Meyerhardt, JA; Niedzwiecki, D; O'Reilly, EM; Shi, Q; Shields, AF; Tan, B; Venook, A; Zemla, T, 2021) |
| "Celecoxib combined with chemotherapy offers more clinical benefits for COX-2 positive advanced gastric cancer patients." | 2.90 | A comprehensive evaluation of clinical efficacy and safety of celecoxib in combination with chemotherapy in metastatic or postoperative recurrent gastric cancer patients: A preliminary, three-center, clinical trial study. ( Chen, Z; Guan, Q; Guo, Q; Li, Q; Liu, M; Wang, J; Wang, Y; Ye, Y; Zhou, Y, 2019) |
| "Preclinical models show that an antiangiogenic regimen at low-dose daily (metronomic) dosing may be effective against chemotherapy-resistant tumors." | 2.79 | A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. ( Allen, JC; Bendel, AE; Campigotto, F; Chi, SN; Chordas, CA; Comito, MA; Goldman, S; Hubbs, SM; Isakoff, MS; Khatib, ZA; Kieran, MW; Kondrat, L; Manley, PE; Neuberg, DS; Pan, WJ; Pietrantonio, JB; Robison, NJ; Rubin, JB; Turner, CD; Werger, AM; Zimmerman, MA, 2014) |
| "Celecoxib was administered at escalating doses of 400, 600, and 800mg/day, starting 3days before the first fraction of radiotherapy and continuing throughout the course of radiotherapy." | 2.76 | Phase I clinical trial of nasopharyngeal radiotherapy and concurrent celecoxib for patients with locoregionally advanced nasopharyngeal carcinoma. ( Bai, SM; Bi, ZF; Liu, YM; Luo, M; Wu, SK; Xue, WP, 2011) |
| "Celecoxib was well tolerated, with similar adverse events and quality-of-life in both arms." | 2.76 | A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. ( Czerniak, BA; De la Cerda, J; Eagle, C; Grossman, HB; Lee, JJ; Lerner, SP; Liu, S; Palmer, JL; Richmond, E; Sabichi, AL; Viner, JL, 2011) |
| "Advanced epithelial ovarian cancer (EOC) is associated with dismal outcome and progression-free survival (PFS) shortens with each subsequent relapse." | 1.51 | Oral metronomic chemotherapy for recurrent & refractory epithelial ovarian cancer: A retrospective analysis. ( Bhatla, N; Khurana, S; Kumar, L; Kumar, S; Malik, PS; Ray, MD; Sharma, A, 2019) |
| "Six patients with thymic neoplasms were treated with capecitabine 1000 mg/m twice daily and celecoxib 200 mg twice daily, day 1 to day 14 on a 21-day cycle." | 1.48 | Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. ( Byron, E; Janisch, L; Salgia, R; Sharma, MR; Wood, K, 2018) |
| "Neutropenia was the main side effect of the metronomic therapy." | 1.38 | Treatment for recurrent medulloblastoma with intrathecal liposomal cytarabine and systemic metronomic combination therapy. ( Kivivuori, SM; Nygaard, R, 2012) |
| "Up to 30% of cancer patients undergoing curative surgery develop local recurrences due to positive margins." | 1.38 | A positive-margin resection model recreates the postsurgical tumor microenvironment and is a reliable model for adjuvant therapy evaluation. ( Aliperti, LA; Cheng, G; Fridlender, ZG; Judy, B; Kapoor, V; Madajewski, B; Okusanya, O; Predina, JD; Quatromoni, J; Singhal, S, 2012) |
| "Tamoxifen and Celebrex were used in 16 patients, 6 had stabilization in growth, 1 had a 50% reduction in the size of the tumor, there was 1 complete regression, and 8 progressed." | 1.35 | Desmoids: a revelation in biology and treatment. ( DiFrancesco, LM; Francis, WP; Kurien, E; Mack, LA; Schachar, NS; Temple, WJ; Zippel, D, 2009) |
| "Celecoxib, which was approved by Health Canada for familial adenomatous polyposis coli, was offered to 27 patients with surgically incurable recurrent melanoma, 87 percent of whom had stage M1c disease." | 1.33 | Clinical activity of celecoxib in metastatic malignant melanoma. ( Wilson, KS, 2006) |
| "Colorectal cancer is one of the leading causes of cancer death." | 1.32 | The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. ( Bardou, M; Barkun, AN; Rahme, E; Toubouti, Y, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 19 (32.76) | 29.6817 |
| 2010's | 33 (56.90) | 24.3611 |
| 2020's | 6 (10.34) | 2.80 |
| Authors | Studies |
|---|---|
| Vierra, M | 1 |
| Dhiman, A | 1 |
| Witmer, HDD | 1 |
| Ulrich, L | 1 |
| Hindi, E | 1 |
| Fenton, E | 1 |
| Shergill, A | 1 |
| Polite, B | 1 |
| Eng, OS | 1 |
| Turaga, KK | 1 |
| Hu, T | 1 |
| Liu, CJ | 1 |
| Yin, X | 1 |
| Tang, W | 1 |
| Yin, L | 1 |
| Bai, H | 1 |
| Liu, F | 1 |
| Wang, D | 1 |
| Li, Y | 1 |
| Sharma, A | 1 |
| Malik, PS | 1 |
| Khurana, S | 1 |
| Kumar, S | 1 |
| Bhatla, N | 1 |
| Ray, MD | 1 |
| Kumar, L | 1 |
| Imaduddin, M | 1 |
| Sultania, M | 1 |
| Vigneshwaran, B | 1 |
| Muduly, DK | 1 |
| Kar, M | 1 |
| Ramanathan, R | 1 |
| Choudry, H | 1 |
| Jones, H | 1 |
| Girgis, M | 1 |
| Gooding, W | 1 |
| Kalinski, P | 1 |
| Bartlett, DL | 2 |
| Meyerhardt, JA | 1 |
| Shi, Q | 1 |
| Fuchs, CS | 1 |
| Meyer, J | 1 |
| Niedzwiecki, D | 1 |
| Zemla, T | 1 |
| Kumthekar, P | 1 |
| Guthrie, KA | 1 |
| Couture, F | 1 |
| Kuebler, P | 1 |
| Bendell, JC | 1 |
| Kumar, P | 1 |
| Lewis, D | 1 |
| Tan, B | 1 |
| Bertagnolli, M | 1 |
| Grothey, A | 1 |
| Hochster, HS | 1 |
| Goldberg, RM | 1 |
| Venook, A | 1 |
| Blanke, C | 1 |
| O'Reilly, EM | 1 |
| Shields, AF | 1 |
| Coombes, RC | 1 |
| Tovey, H | 1 |
| Kilburn, L | 1 |
| Mansi, J | 1 |
| Palmieri, C | 1 |
| Bartlett, J | 1 |
| Hicks, J | 1 |
| Makris, A | 1 |
| Evans, A | 1 |
| Loibl, S | 1 |
| Denkert, C | 1 |
| Murray, E | 1 |
| Grieve, R | 1 |
| Coleman, R | 1 |
| Borley, A | 1 |
| Schmidt, M | 1 |
| Rautenberg, B | 1 |
| Kunze, CA | 1 |
| Rhein, U | 1 |
| Mehta, K | 1 |
| Mousa, K | 1 |
| Dibble, T | 1 |
| Lu, XL | 1 |
| von Minckwitz, G | 1 |
| Bliss, JM | 1 |
| Wood, K | 1 |
| Byron, E | 1 |
| Janisch, L | 1 |
| Salgia, R | 1 |
| Sharma, MR | 1 |
| Benech, N | 1 |
| Walter, T | 1 |
| Saurin, JC | 1 |
| Yang, S | 1 |
| Wang, X | 2 |
| Jiang, H | 1 |
| Wang, Y | 3 |
| Li, Z | 1 |
| Lu, H | 1 |
| Berthold, F | 1 |
| Hömberg, M | 1 |
| Proleskovskaya, I | 1 |
| Mazanek, P | 2 |
| Belogurova, M | 1 |
| Ernst, A | 1 |
| Sterba, J | 2 |
| Hawk, E | 1 |
| Maresso, KC | 1 |
| Brown, P | 1 |
| Mohammed, A | 1 |
| Yarla, NS | 1 |
| Madka, V | 1 |
| Rao, CV | 1 |
| Kelly, JD | 2 |
| Tan, WS | 1 |
| Porta, N | 1 |
| Mostafid, H | 1 |
| Huddart, R | 1 |
| Protheroe, A | 1 |
| Bogle, R | 1 |
| Blazeby, J | 1 |
| Palmer, A | 1 |
| Cresswell, J | 1 |
| Johnson, M | 1 |
| Brough, R | 1 |
| Madaan, S | 1 |
| Andrews, S | 1 |
| Cruickshank, C | 1 |
| Burnett, S | 1 |
| Maynard, L | 1 |
| Hall, E | 2 |
| Gore, JL | 1 |
| Wright, JL | 1 |
| Goldstein, MR | 1 |
| Mascitelli, L | 1 |
| Guo, Q | 1 |
| Li, Q | 1 |
| Wang, J | 2 |
| Liu, M | 1 |
| Chen, Z | 1 |
| Ye, Y | 1 |
| Guan, Q | 1 |
| Zhou, Y | 1 |
| Gupta, R | 1 |
| Cristea, M | 1 |
| Frankel, P | 1 |
| Ruel, C | 1 |
| Chen, C | 1 |
| Morgan, R | 1 |
| Leong, L | 1 |
| Chow, W | 1 |
| Koczywas, M | 1 |
| Koehler, S | 1 |
| Lim, D | 1 |
| Luu, T | 1 |
| Martel, C | 1 |
| McNamara, M | 1 |
| Somlo, G | 1 |
| Twardowski, P | 1 |
| Yen, Y | 1 |
| Idorenyi, A | 1 |
| Raechelle, T | 1 |
| Carroll, M | 1 |
| Chung, V | 1 |
| Patil, V | 1 |
| Noronha, V | 1 |
| Krishna, V | 1 |
| Joshi, A | 1 |
| Prabhash, K | 1 |
| Johnson, K | 1 |
| Notrica, DM | 1 |
| Carpentieri, D | 1 |
| Jaroszewski, D | 1 |
| Henry, MM | 1 |
| Kraus, S | 1 |
| Hummler, S | 1 |
| Toriola, AT | 1 |
| Poole, EM | 1 |
| Scherer, D | 1 |
| Kotzmann, J | 1 |
| Makar, KW | 1 |
| Kazanov, D | 1 |
| Galazan, L | 1 |
| Naumov, I | 1 |
| Coghill, AE | 1 |
| Duggan, D | 1 |
| Gigic, B | 1 |
| Arber, N | 1 |
| Ulrich, CM | 1 |
| Carvajal-Carmona, LG | 1 |
| Chu, JH | 1 |
| Zauber, AG | 2 |
| Kubo, M | 1 |
| Matsuda, K | 1 |
| Dunlop, M | 1 |
| Houlston, RS | 1 |
| Sieber, O | 1 |
| Lipton, L | 1 |
| Gibbs, P | 1 |
| Martin, NG | 1 |
| Montgomery, GW | 1 |
| Young, J | 1 |
| Baird, PN | 1 |
| Ratain, MJ | 1 |
| Nakamura, Y | 1 |
| Weiss, ST | 1 |
| Tomlinson, I | 1 |
| Bertagnolli, MM | 2 |
| Robison, NJ | 1 |
| Campigotto, F | 1 |
| Chi, SN | 1 |
| Manley, PE | 1 |
| Turner, CD | 1 |
| Zimmerman, MA | 1 |
| Chordas, CA | 1 |
| Werger, AM | 1 |
| Allen, JC | 1 |
| Goldman, S | 1 |
| Rubin, JB | 1 |
| Isakoff, MS | 1 |
| Pan, WJ | 1 |
| Khatib, ZA | 1 |
| Comito, MA | 1 |
| Bendel, AE | 1 |
| Pietrantonio, JB | 1 |
| Kondrat, L | 1 |
| Hubbs, SM | 1 |
| Neuberg, DS | 1 |
| Kieran, MW | 1 |
| Generali, D | 1 |
| Buffa, FM | 1 |
| Deb, S | 1 |
| Cummings, M | 1 |
| Reid, LE | 1 |
| Taylor, M | 1 |
| Andreis, D | 1 |
| Allevi, G | 1 |
| Ferrero, G | 1 |
| Byrne, D | 1 |
| Martinotti, M | 1 |
| Bottini, A | 1 |
| Harris, AL | 1 |
| Lakhani, SR | 1 |
| Fox, SB | 1 |
| Kast, RE | 1 |
| Karpel-Massler, G | 1 |
| Halatsch, ME | 1 |
| Wong, ET | 1 |
| Lok, E | 1 |
| Swanson, KD | 1 |
| Gan, ZM | 1 |
| Wang, XD | 1 |
| Lv, DH | 1 |
| Liu, D | 1 |
| Li, L | 1 |
| Lee, DY | 1 |
| Lim, JH | 1 |
| Kim, YJ | 1 |
| Kim, SD | 1 |
| Park, SW | 1 |
| Kwon, SK | 1 |
| Hah, JH | 1 |
| Kwon, TK | 1 |
| Kim, KH | 2 |
| Kim, YH | 1 |
| Sung, MW | 2 |
| Ju, RJ | 1 |
| Zeng, F | 1 |
| Liu, L | 1 |
| Mu, LM | 1 |
| Xie, HJ | 1 |
| Zhao, Y | 1 |
| Yan, Y | 1 |
| Wu, JS | 1 |
| Hu, YJ | 1 |
| Lu, WL | 1 |
| Schneider, BJ | 1 |
| Kalemkerian, GP | 1 |
| Kraut, MJ | 1 |
| Wozniak, AJ | 1 |
| Worden, FP | 1 |
| Smith, DW | 1 |
| Chen, W | 1 |
| Gadgeel, SM | 1 |
| Francis, WP | 1 |
| Zippel, D | 1 |
| Mack, LA | 1 |
| DiFrancesco, LM | 1 |
| Kurien, E | 1 |
| Schachar, NS | 1 |
| Temple, WJ | 2 |
| Eagle, CJ | 1 |
| Redston, M | 1 |
| Breazna, A | 1 |
| Kim, K | 1 |
| Tang, J | 1 |
| Rosenstein, RB | 1 |
| Umar, A | 1 |
| Bagheri, D | 1 |
| Collins, NT | 1 |
| Burn, J | 1 |
| Chung, DC | 1 |
| Dewar, T | 1 |
| Foley, TR | 1 |
| Hoffman, N | 1 |
| Macrae, F | 1 |
| Pruitt, RE | 1 |
| Saltzman, JR | 1 |
| Salzberg, B | 1 |
| Sylwestrowicz, T | 1 |
| Hawk, ET | 1 |
| Limsukon, A | 1 |
| Susanto, I | 1 |
| Soo Hoo, GW | 1 |
| Dubinett, SM | 1 |
| Batra, RK | 1 |
| Walbert, T | 1 |
| Gilbert, MR | 1 |
| Groves, MD | 1 |
| Puduvalli, VK | 1 |
| Yung, WK | 1 |
| Conrad, CA | 1 |
| Bobustuc, GC | 1 |
| Colman, H | 1 |
| Hsu, SH | 1 |
| Bekele, BN | 1 |
| Qiao, W | 1 |
| Levin, VA | 1 |
| Xue, WP | 1 |
| Bai, SM | 1 |
| Luo, M | 1 |
| Bi, ZF | 1 |
| Liu, YM | 1 |
| Wu, SK | 1 |
| Lustberg, MB | 1 |
| Povoski, SP | 1 |
| Zhao, W | 1 |
| Ziegler, RM | 1 |
| Sugimoto, Y | 1 |
| Ruppert, AS | 1 |
| Lehman, AM | 1 |
| Shiels, DR | 1 |
| Mrozek, E | 1 |
| Ramaswamy, B | 1 |
| Layman, RM | 1 |
| Brueggemeier, RW | 1 |
| Shapiro, CL | 1 |
| Sabichi, AL | 1 |
| Lee, JJ | 1 |
| Grossman, HB | 1 |
| Liu, S | 1 |
| Richmond, E | 1 |
| Czerniak, BA | 1 |
| De la Cerda, J | 1 |
| Eagle, C | 1 |
| Viner, JL | 1 |
| Palmer, JL | 1 |
| Lerner, SP | 1 |
| Edelman, MJ | 1 |
| Hodgson, L | 1 |
| Christenson, R | 1 |
| Jewell, S | 1 |
| Vokes, E | 1 |
| Kratzke, R | 1 |
| Nygaard, R | 1 |
| Kivivuori, SM | 1 |
| Choudry, HA | 1 |
| Mavanur, A | 1 |
| O'Malley, ME | 1 |
| Zeh, HJ | 1 |
| Guo, Z | 1 |
| Predina, JD | 1 |
| Judy, B | 1 |
| Fridlender, ZG | 1 |
| Aliperti, LA | 1 |
| Madajewski, B | 1 |
| Kapoor, V | 1 |
| Cheng, G | 1 |
| Quatromoni, J | 1 |
| Okusanya, O | 1 |
| Singhal, S | 1 |
| Rahme, E | 1 |
| Barkun, AN | 1 |
| Toubouti, Y | 1 |
| Bardou, M | 1 |
| Pruthi, RS | 1 |
| Derksen, JE | 1 |
| Moore, D | 1 |
| Reardon, DA | 1 |
| Quinn, JA | 1 |
| Vredenburgh, J | 1 |
| Rich, JN | 1 |
| Gururangan, S | 1 |
| Badruddoja, M | 1 |
| Herndon, JE | 1 |
| Dowell, JM | 1 |
| Friedman, AH | 1 |
| Friedman, HS | 1 |
| Roh, JL | 1 |
| Wu, R | 1 |
| Abramson, AL | 1 |
| Shikowitz, MJ | 1 |
| Dannenberg, AJ | 1 |
| Steinberg, BM | 1 |
| Csiki, I | 1 |
| Morrow, JD | 1 |
| Sandler, A | 1 |
| Shyr, Y | 1 |
| Oates, J | 1 |
| Williams, MK | 1 |
| Dang, T | 1 |
| Carbone, DP | 1 |
| Johnson, DH | 1 |
| DuBois, RN | 1 |
| Smith, MR | 1 |
| Manola, J | 1 |
| Kaufman, DS | 1 |
| Oh, WK | 1 |
| Bubley, GJ | 1 |
| Kantoff, PW | 1 |
| Valik, D | 1 |
| Mudry, P | 1 |
| Kepak, T | 1 |
| Pavelka, Z | 1 |
| Bajciova, V | 1 |
| Zitterbart, K | 1 |
| Kadlecova, V | 1 |
| Stempak, D | 1 |
| Gammon, J | 1 |
| Halton, J | 1 |
| Moghrabi, A | 1 |
| Koren, G | 1 |
| Baruchel, S | 1 |
| Wilson, KS | 1 |
| Zippel, DB | 1 |
| Kesari, S | 1 |
| Schiff, D | 1 |
| Doherty, L | 1 |
| Gigas, DC | 1 |
| Batchelor, TT | 1 |
| Muzikansky, A | 1 |
| O'Neill, A | 1 |
| Drappatz, J | 1 |
| Chen-Plotkin, AS | 1 |
| Ramakrishna, N | 1 |
| Weiss, SE | 1 |
| Levy, B | 1 |
| Bradshaw, J | 1 |
| Kracher, J | 1 |
| Laforme, A | 1 |
| Black, PM | 1 |
| Folkman, J | 1 |
| Kieran, M | 1 |
| Wen, PY | 1 |
| Riedel, SB | 1 |
| Fischer, SM | 1 |
| Sanders, BG | 1 |
| Kline, K | 1 |
| Tuma, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Temozolomide and Irinotecan Consolidation in Patients With MGMT Silenced, Microsatellite Stable Colorectal Cancer With Persistence of Minimal Residual Disease in Liquid Biopsy After Standard Adjuvant Chemotherapy: the ERASE-TMZ Study[NCT05031975] | Phase 2 | 35 participants (Anticipated) | Interventional | 2022-05-02 | Recruiting | ||
| A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer[NCT01150045] | Phase 3 | 2,527 participants (Actual) | Interventional | 2010-06-30 | Active, not recruiting | ||
| A Phase III Multicentre Double Blind Randomised Trial of Celecoxib Versus Placebo in Primary Breast Cancer Patients[NCT02429427] | Phase 3 | 2,639 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| A Drug-drug Interaction Study of Capecitabine and Celecoxib in Patients With Advanced Solid Malignancies[NCT01705106] | Phase 1 | 21 participants (Actual) | Interventional | 2012-08-29 | Terminated (stopped due to The study was terminated early due to slow accrual.) | ||
| Phase 2 Trial of Metronomic Treatment in Children and Adolescents With Recurrent or Progressive Neuroblastoma (NB)[NCT02641314] | Phase 2 | 26 participants (Anticipated) | Interventional | 2016-12-22 | Recruiting | ||
| Anti-Angiogenic Chemotherapy: A Phase II Trial of the Oral 5-Drug Regimen (Thalidomide, Celecoxib, Fenofibrate, Etoposide and Cyclophosphamide) in Patients With Relapsed or Progressive Cancer[NCT00357500] | Phase 2 | 101 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Evaluation Of Celecoxib In Combination With Docetaxel In The Treatment Of Advanced Non-Small Cell Lung Cancer Patients Previously Treated With Platinum Based Chemotherapy[NCT00030420] | Phase 2 | 24 participants (Actual) | Interventional | 2001-10-31 | Completed | ||
| A Multicentered Randomized Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis[NCT00571701] | Phase 2 | 50 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Disease-Free Survival (DFS) is defined as the time of randomization until documented progression or death from any cause. The endpoint of this trial is to compare disease-free survival of patients with stage III colon cancer randomized to standard chemotherapy only (FOLFOX; Arm A and Arm C) or standard chemotherapy (FOLFOX) with 3 years of celecoxib 400 mg daily (Arm B and Arm D). The percentage of patients who were alive and disease free after 3 years are reported here. A log-rank test stratified with the stratification factors was used to compare disease-free survival (celecoxib vs placebo) (NCT01150045)
Timeframe: At 3 years of follow-up
| Intervention | percentage of participants (Number) |
|---|---|
| FOLFOX and Placebo (Arms A +C) | 73.4 |
| FOLFOX Plus Celecoxib Daily (Arms B + D) | 76.3 |
Overall Survival (DFS) is defined as the time of randomization until documented death from any cause. The endpoint is to compare overall survival of patients with stage III colon cancer randomized to standard chemotherapy only (FOLFOX; Arm A and Arm C) or standard chemotherapy (FOLFOX) with 5 years of celecoxib 400 mg daily (Arm B and Arm D). The percentage of patients who were alive after 3 years are reported here. (NCT01150045)
Timeframe: up to 3 years from registration
| Intervention | percentage of participants (Number) |
|---|---|
| FOLFOX and Placebo (Arms A +C) | 81.6 |
| FOLFOX Plus Celecoxib Daily (Arms B + D) | 84.3 |
Number of deaths recorded as having cardiovascular involvement are reported by treatment group. (NCT02429427)
Timeframe: Patients are followed up to 10 years, any deaths within this timeframe with cardiovascular involvement reported are included in the analysis.
| Intervention | Participants (Count of Participants) |
|---|---|
| Celecoxib | 6 |
| Placebo | 5 |
Any malignant contralateral breast disease will be included and recorded as a second primary (NCT02429427)
Timeframe: From randomisation until a second primary breast cancer is diagnosed. Patients will be followed up to 10 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| Celecoxib | 19 |
| Placebo | 12 |
From time of randomisation to the date of first event; with events contributing to the analysis defined as loco-regional and distant breast cancer recurrence, new primary breast cancer (ipsilateral or contralateral) and death without disease relapse (intercurrent death) (NCT02429427)
Timeframe: Patients will be followed up to 10 years. DFS will be calculated from date of randomization until the date of first documented DFS event, this will be assessed at 2 and 5 years
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| 2 Year DFS rate | 5 Year DFS rate | |
| Celecoxib | 91 | 84 |
| Placebo | 90 | 83 |
First local recurrence and first distant recurrence will be recorded on separate parts of the CRF. In the event of local progression, all patients must be followed up for distant recurrence, second malignancy and survival. Similarly in the case of second malignancy, the appropriate CRF should be completed and patients should REACT Protocol, Version 39, dated 01.11.2016 Page 34 of 48 continue to be followed for disease progression and where possible the relation of any subsequent disease progression and/or death due to the primary or second cancer should be established. (NCT02429427)
Timeframe: Date of randomisation until the date of death from any cause or censored at the date the patient was last seen alive, this will be assessed at 2 and 5 years
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| 2 Year | 5 Year | |
| Celecoxib | 97 | 90 |
| Placebo | 96 | 91 |
27-week overall survival is the probability of patients remaining alive at 27-weeks from study entry estimated using with Kaplan-Meier methods. (NCT00357500)
Timeframe: Assessed every 9 weeks on treatment and annually until death or initiation of new therapy, up to 27 weeks.
| Intervention | Probability (Number) |
|---|---|
| 5-drug Metronomic Antiangiogenic Regimen | 0.61 |
27-week progression-free survival is the probability of patients remaining alive and progression-free at 27-weeks from study entry estimated using Kaplan-Meier methods. As appropriate for tumor type and location, gadolinium-enhanced MRI and other imaging modalites were used to assess response. Progressive disease was defined as >/=25% increase in product of diameters, development of new areas of disease, or disease-attributable clinical deterioration or death, progressive disease. For patients with leukemia PD was defined as >/=25% or >/=5,000 cells/mm3 increase in number of circulating cells, development of extramedullary disease, or other clinical evidence of progression. (NCT00357500)
Timeframe: Assessed every 9 weeks on treatment and annually until death or initiation of new therapy, up to 27 weeks.
| Intervention | Probability (Number) |
|---|---|
| 5-drug Metronomic Antiangiogenic Regimen | 0.31 |
Proportion of patients alive at 27 weeks without progressive disease (PD) and having tolerated therapy. As appropriate for tumor type and location, gadolinium-enhanced MRI and other imaging modalites were used to assess response. Progressive disease was defined as >/=25% increase in product of diameters, development of new areas of disease, or disease-attributable clinical deterioration or death, progressive disease. For patients with leukemia PD was defined as >/=25% or >/=5,000 cells/mm3 increase in number of circulating cells, development of extramedullary disease, or other clinical evidence of progression. (NCT00357500)
Timeframe: 27 weeks
| Intervention | proportion of patients (Number) |
|---|---|
| 5-drug Metronomic Antiangiogenic Regimen | .25 |
As appropriate for tumor type and location, gadolinium-enhanced MRI and other imaging modalites were used to assess response. Best response was regarded as best response at any single assessment. Response was defined as follows: complete resolution of all demonstrable tumor, complete response (CR); >/=50% decrease in the product of the 2 maximum perpendicular diameters relative to the baseline evaluation, partial response (PR); <50% decrease and <25% increase in product of diameters, stable disease (SD); and >/=25% increase in product of diameters, development of new areas of disease, or disease-attributable clinical deterioration or death, progressive disease (PD). For patients with leukemia PD was defined as >/=25% or >/=5,000 cells/mm3 increase in number of circulating cells, development of extramedullary disease, or other clinical evidence of progression. (NCT00357500)
Timeframe: Assessed at study entry, every 9 weeks on treatment and at treatment discontinuation, up to 27 weeks.
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Complete Response | Partial Response | Stable Disease | Progressive Disease | Not Evaluable | |
| 5-drug Metronomic Antiangiogenic Regimen | 1 | 12 | 36 | 47 | 1 |
Mean plasma levels of celecoxib over months 3-12 in first treatment period correlated with reduction in papilloma growth rate greater than 50% during the last 3 months of first treatment period compared to baseline. (NCT00571701)
Timeframe: Baseline to 12 months
| Intervention | pg. celecoxib/ml. plasma (Mean) |
|---|---|
| Responders | 151.3 |
| Non-responders | 543.41 |
Percent of patients of each gender with reduction in papilloma growth rate greater than 50% during the last 3 months of first treatment period compared to baseline (NCT00571701)
Timeframe: Baseline to12 months
| Intervention | percent responders (Number) |
|---|---|
| Celecoxib First - Males | 12.50 |
| Placebo First- Males | 40.00 |
| Celecoxib First- Females | 12.50 |
| Placebo First- Females | 0.00 |
Percent of patients with HPV 6 versus patients with HPV 11 with reduction in papilloma growth rate greater than 50% during the last 3 months of first treatment period compared to baseline. (NCT00571701)
Timeframe: Baseline to 12 months
| Intervention | percent of responders (Number) |
|---|---|
| Celecoxib First - HPV 6 | 9.09 |
| Placebo First- HPV 6 | 42.86 |
| Celecoxib First- HPV 11 | 25.00 |
| Placebo First- HPV 11 | 0.00 |
Percent of juvenile versus adult onset patients with reduction in papilloma growth rate greater than 50% during the last 3 months of first treatment period compared to baseline. (NCT00571701)
Timeframe: Baseline to 12 months
| Intervention | percentage of responders (Number) |
|---|---|
| Celecoxib First- Juvenile Onset | 12.50 |
| Placebo First- Juvenile-onsent | 7.69 |
| Celecoxib First - Adult Onset | 12.50 |
| Placebo First- Adult-onset | 33.33 |
Percent of patients who responded to celecoxib with increase in papilloma growth rate of no greater than 0.01 at end of second treatment period compared to growth rate at end of first treatment period. (NCT00571701)
Timeframe: End of first treatment period (month 12) to end of second treatment period (month 24)
| Intervention | percent of patients (Number) |
|---|---|
| Celecoxib Responders-maintained | 100 |
Change in mean growth rates during the last 3 months of the first treatment period compared to the mean values at baseline. Endoscopy and removal of all tumor was done every 3 months. Growth rate is calculated as the scored amount of papilloma recurrence in a 3 month period divided by the exact number of days since last endoscopy and removal of all tumor. (NCT00571701)
Timeframe: Baseline to 12 months
| Intervention | percent change in mean growth rate (Mean) |
|---|---|
| Celecoxib First, Then Placebo | -5.4 |
| Placebo First, Then Celecoxib | -15.2 |
Percent of patients with reduction in papilloma growth rate greater than 50% during the last 3 months of first treatment period compared to baseline (NCT00571701)
Timeframe: Baseline to 12 months
| Intervention | percent responders (Number) |
|---|---|
| Celecoxib First (12 Months), Then Placebo (12 Months) | 12.5 |
| Placebo First (12 Months), Then Celecoxib (12 Months) | 28.6 |
4 reviews available for celecoxib and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Selective COX-2 inhibitors do not increase gastrointestinal reactions after colorectal cancer surgery: a systematic review and meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitor | 2023 |
Clinically Relevant Anti-Inflammatory Agents for Chemoprevention of Colorectal Cancer: New Perspectives.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Ce | 2018 |
Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study.
Topics: Adenoma; Anticarcinogenic Agents; Case-Control Studies; Celecoxib; Colorectal Neoplasms; Female; Gen | 2013 |
Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Survival Results From STAMPEDE (NCT00268476).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Density Conservation Agents; | 2016 |
24 trials available for celecoxib and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Phase II Trial of Adjuvant Dendritic Cell Vaccine in Combination with Celecoxib, Interferon-α, and Rintatolimod in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Cytoreduction Surgi | 2021 |
Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Chemother | 2021 |
Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Chemother | 2021 |
Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Chemother | 2021 |
Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Chemother | 2021 |
Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ce | 2021 |
Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma.
Topics: Administration, Metronomic; Adult; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Child; | 2017 |
BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004).
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherap | 2019 |
A comprehensive evaluation of clinical efficacy and safety of celecoxib in combination with chemotherapy in metastatic or postoperative recurrent gastric cancer patients: A preliminary, three-center, clinical trial study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Capecitabine; Celecoxib; Chemotherapy, Adjuvant; Dis | 2019 |
Randomized trial of oral cyclophosphamide versus oral cyclophosphamide with celecoxib for recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents | 2019 |
Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Celecoxib; Col | 2013 |
A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Celecoxi | 2014 |
COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplas | 2014 |
[Perioperative immunomodulatory therapy does not decrease postoperative recurrence rate of rectal cancer].
Topics: C-Reactive Protein; Celecoxib; Cyclooxygenase 2 Inhibitors; Humans; Immunomodulation; Inflammation; | 2015 |
Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecox | 2008 |
Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Celecoxib; Colonoscopy; Colorectal | 2009 |
Phase I clinical trial of nasopharyngeal radiotherapy and concurrent celecoxib for patients with locoregionally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Celecoxib; Combined Modality Therapy; Cyclooxygenase 2 Inhibi | 2011 |
Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lobular | 2011 |
A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer.
Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female; Follow-Up Studies; Humans; Male | 2011 |
Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arac | 2011 |
A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.
Topics: Antineoplastic Agents; Celecoxib; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase 2 Inhi | 2004 |
Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Brain Neoplasm | 2005 |
Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inducing Agents; Antineoplastic Agents, Phytogenic; Ant | 2005 |
Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy.
Topics: Aged; Celecoxib; Chemotherapy, Adjuvant; Cyclooxygenase 2 Inhibitors; Humans; Male; Middle Aged; Neo | 2006 |
Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study.
Topics: Administration, Oral; Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemothera | 2006 |
A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cel | 2006 |
Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasm | 2007 |
30 other studies available for celecoxib and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Celecoxib and Myrtol: A Novel Therapy for Recurrent Appendiceal Mucinous Neoplasms With Extensive Peritoneal Dissemination.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; C | 2022 |
Oral metronomic chemotherapy for recurrent & refractory epithelial ovarian cancer: A retrospective analysis.
Topics: Administration, Metronomic; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Com | 2019 |
Metronomic therapy using Methotrexate and Celecoxib: A Boon for Oral Cancer patients during COVID-19 Pandemic.
Topics: Carcinoma; Celecoxib; Cisplatin; COVID-19; Humans; Methotrexate; Mouth Neoplasms; Neoplasm Recurrenc | 2021 |
Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Celecoxib; Female; Follow-Up Stu | 2018 |
Desmoid Tumors and Celecoxib with Sorafenib.
Topics: Adenomatous Polyposis Coli; Adult; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Female | 2017 |
Effective treatment of aggressive fibromatosis with celecoxib guided by genetic testing.
Topics: Adult; beta Catenin; Biopsy; Celecoxib; Cyclooxygenase 2 Inhibitors; Fibromatosis, Aggressive; Genet | 2017 |
NSAIDs to Prevent Breast Cancer Recurrence? An Unanswered Question.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aromatase Inhibitors; Aspirin; Breast Neoplasms; Celecoxib; | 2018 |
Can We Prevent Bladder Cancer Recurrences?
Topics: Carcinoma, Transitional Cell; Celecoxib; Humans; Neoplasm Recurrence, Local; Urinary Bladder Neoplas | 2019 |
Re: John L. Gore, Jonathan L. Wright. Can We Prevent Bladder Cancer Recurrences? Eur Urol 2019;75:602-3.
Topics: Carcinoma, Transitional Cell; Celecoxib; Humans; Neoplasm Recurrence, Local; Urinary Bladder Neoplas | 2019 |
Oral metronomic chemotherapy in recurrent, metastatic and locally advanced head and neck cancers.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2013 |
Successful treatment of recurrent pediatric inflammatory myofibroblastic tumor in a single patient with a novel chemotherapeutic regimen containing celecoxib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Child; Humans; Ifosfamide; Lung Neoplasms | 2013 |
CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Artemisinins; Artesunate; Auran | 2014 |
Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkyla | 2015 |
Effect of Celecoxib on Survival of Mobile Tongue Cancer.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease-Free Survival | 2015 |
Destruction of vasculogenic mimicry channels by targeting epirubicin plus celecoxib liposomes in treatment of brain glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blood-Brain Barrier; Brain Neopl | 2016 |
Desmoids: a revelation in biology and treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Celecoxib; Chemothera | 2009 |
Regression of recurrent respiratory papillomatosis with celecoxib and erlotinib combination therapy.
Topics: Biopsy; Bronchoscopy; Celecoxib; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Erlotinib Hyd | 2009 |
Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Capecitabine; Celecoxi | 2011 |
Boxing bladder cancer with COX-2-specific inhibition.
Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Female; Humans; Male; Neoplasm Recurrence, Local; Pyrazoles; | 2011 |
Treatment for recurrent medulloblastoma with intrathecal liposomal cytarabine and systemic metronomic combination therapy.
Topics: Administration, Metronomic; Adolescent; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherap | 2012 |
Chronic anti-inflammatory drug therapy inhibits gel-forming mucin production in a murine xenograft model of human pseudomyxoma peritonei.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Appendiceal Neoplasms; Celecoxib; Colonic N | 2012 |
A positive-margin resection model recreates the postsurgical tumor microenvironment and is a reliable model for adjuvant therapy evaluation.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Celecoxib; Cell Line, Tumor; Chemotherapy, A | 2012 |
The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence.
Topics: Adenoma; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Cel | 2003 |
Suppression of accelerated tumor growth in surgical wounds by celecoxib and indomethacin.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma; Carcinoma, Squamous Cell; Celecoxib; Ce | 2005 |
Epidermal growth factor-induced cyclooxygenase-2 expression is mediated through phosphatidylinositol-3 kinase, not mitogen-activated protein/extracellular signal-regulated kinase kinase, in recurrent respiratory papillomas.
Topics: Apoptosis; Blotting, Western; Celecoxib; Cell Proliferation; Cells, Cultured; Cyclooxygenase 2; Cycl | 2005 |
Cyclooxygenase-2 selective inhibitors and prostate cancer: what is the clinical benefit?
Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Humans; Male; Neoplasm Recurrence, Local; Prostate-Specific | 2006 |
Clinical activity of celecoxib in metastatic malignant melanoma.
Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Female; Humans; Male; Melano | 2006 |
When is a neoplasm not a neoplasm? When it is a desmoid.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Hormonal; Celecoxib; Fibromatosis, A | 2007 |
Vitamin E analog, alpha-tocopherol ether-linked acetic acid analog, alone and in combination with celecoxib, reduces multiplicity of ultraviolet-induced skin cancers in mice.
Topics: Acetates; Administration, Inhalation; Animals; Antineoplastic Combined Chemotherapy Protocols; Carci | 2008 |
Drugs to prevent colon cancer show promise, but hurdles remain for chemoprevention.
Topics: Adenoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Prot | 2008 |